Table 3.
Two Stage Survival Analysis, the Shanghai Breast Cancer Study and the Shanghai Breast Cancer Survival Study
| Gene and SNP * Study Stage | Overall Survival HR (95% CI) **
|
Disease Free Survival HR (95% CI) **
|
||||
|---|---|---|---|---|---|---|
| AB | BB | p-value | AB | BB | p-value | |
| CCND1 rs9344 (A/G) | ||||||
| Study Stage 1 | 1.4 (1.0-1.9) | 1.6 (1.1-2.3) | 0.015 | 1.3 (1.0-1.7) | 1.3 (0.9-1.9) | 0.080 |
| Study Stage 2 | 1.0 (0.8-1.2) | 1.0 (0.7-1.3) | 0.820 | 0.9 (0.8-1.1) | 0.9 (0.7-1.1) | 0.200 |
| Combined | 1.1 (0.9-1.2) | 1.1 (0.9-1.4) | 0.325 | 1.0 (0.9-1.2) | 1.0 (0.8-1.2) | 0.744 |
| COMT rs4680 (G/A) | ||||||
| Study Stage 1 | 1.0 (0.8-1.4) | 1.3 (0.8-2.3) | 0.393 | 1.0 (0.8-1.3) | 1.7 (1.1-2.7) | 0.084 |
| Study Stage 2 | 1.5 (1.0-2.2) | 1.3 (0.6-2.9) | 0.123 | 1.2 (0.8-1.8) | 0.9 (0.4-2.1) | 0.560 |
| Combined | 1.1 (0.9-1.5) | 1.3 (0.8-2.0) | 0.151 | 1.1 (0.9-1.3) | 1.5 (1.0-2.1) | 0.094 |
| MMP7 rs11568818 (A/G) | ||||||
| Study Stage 1 | 1.1 (0.8-1.5) | 6.7 (2.4-18.7) | 0.137 | 1.1 (0.8-1.5) | 5.0 (1.8-13.9) | 0.146 |
| Study Stage 2 | 1.0 (0.7-1.4) | 0.5 (0.1-3.7) | 0.821 | 1.1 (0.8-1.4) | 0.4 (0.1-2.9) | 0.978 |
| Combined | 1.0 (0.8-1.3) | 2.0 (0.8-4.9) | 0.478 | 1.1 (0.9-1.3) | 1.6 (0.7-3.8) | 0.380 |
| MMP7 rs11225297 (A/T) | ||||||
| Study Stage 1 | 0.7 (0.5-0.9) | 0.3 (0.1-0.9) | 0.002 | 0.8 (0.7-1.1) | 0.4 (0.2-0.8) | 0.016 |
| Study Stage 2 | 0.9 (0.7-1.2) | 0.6 (0.2-1.3) | 0.243 | 0.9 (0.7-1.1) | 1.2 (0.8-2.0) | 0.927 |
| Combined | 0.8 (0.7-1.0) | 0.4 (0.2-0.8) | 0.003 | 0.9 (0.8-1.1) | 0.8 (0.5-1.2) | 0.095 |
| MMP8 rs11225395 (C/T) | ||||||
| Study Stage 1 | 0.8 (0.6-1.1) | 0.5 (0.3-0.8) | 0.007 | 0.8 (0.6-1.0) | 0.8 (0.5-1.2) | 0.094 |
| Study Stage 2 | 0.9 (0.6-1.3) | 0.8 (0.4-1.5) | 0.375 | 1.1 (0.7-1.6) | 1.1 (0.6-2.1) | 0.594 |
| Combined | 0.9 (0.7-1.1) | 0.6 (0.4-0.9) | 0.021 | 0.9 (0.7-1.1) | 0.9 (0.7-1.2) | 0.353 |
| MMP12 rs652438 (A/G) | ||||||
| Study Stage 1 | 1.5 (1.1-2.2) | 0.5 (0.1-2.1) | 0.184 | 1.4 (1.0-1.9) | 0.6 (0.2-1.8) | 0.311 |
| Study Stage 2 | 0.8 (0.6-1.2) | 0.4 (0.1-1.8) | 0.141 | 0.9 (0.7-1.2) | 0.9 (0.4-2.2) | 0.490 |
| Combined | 1.1 (0.8-1.3) | 0.5 (0.2-1.3) | 0.759 | 1.1 (0.9-1.3) | 0.8 (0.4-1.6) | 0.752 |
| PAI1 rs1799889 (4G/5G) | ||||||
| Study Stage 1 | 0.8 (0.6-1.0) | 0.7 (0.5-1.0) | 0.037 | 0.8 (0.6-1.0) | 0.6 (0.4-0.9) | 0.006 |
| Study Stage 2 | 1.2 (0.9-1.6) | 1.2 (0.9-1.8) | 0.219 | 1.1 (0.8-1.4) | 1.1 (0.8-1.5) | 0.434 |
| Combined | 1.0 (0.8-1.2) | 1.0 (0.8-1.3) | 0.804 | 1.0 (0.8-1.1) | 0.9 (0.7-1.1) | 0.232 |
| TGFB1 rs1800470 (C/T) | ||||||
| Study Stage 1 | 1.1 (0.8-1.6) | 1.0 (0.7-1.5) | 0.944 | 1.0 (0.7-1.2) | 0.9 (0.6-1.2) | 0.427 |
| Study Stage 2 | 1.2 (0.9-1.5) | 0.8 (0.6-1.2) | 0.326 | 1.2 (0.9-1.5) | 1.0 (0.7-1.4) | 0.841 |
| Combined | 1.2 (0.9-1.4) | 0.9 (0.7-1.2) | 0.523 | 1.1 (0.9-1.3) | 1.0 (0.8-1.2) | 0.774 |
| VEGFA rs2010963 (G/C) | ||||||
| Study Stage 1 | 0.7 (0.5-1.0) | 0.7 (0.5-1.0) | 0.033 | 0.8 (0.6-1.0) | 0.8 (0.6-1.1) | 0.102 |
| Study Stage 2 | 1.3 (1.0-1.7) | 1.0 (0.7-1.5) | 0.602 | 1.1 (0.9-1.4) | 1.0 (0.7-1.3) | 0.904 |
| Combined | 1.0 (0.8-1.2) | 0.9 (0.7-1.1) | 0.338 | 1.0 (0.8-1.1) | 0.9 (0.7-1.1) | 0.320 |
*
Gene name, SNP rs number, and alleles (major / minor alleles among genotyped SBCS/SBCSS participants)
**
Proportional hazards regression; adjusted for age at diagnosis, disease stage, ER, PR, and treatment (chemotherapy, radiotherapy, and tamoxifen); combined analysis additionally adjusted for study stage; AA major allele homozygotes (reference group); AB heterozygotes; BB minor allele homozygotes; p-value for additive trend